|
1
|
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
|
J Clin Oncol
|
2007
|
5.23
|
|
2
|
Physician visits prior to treatment for clinically localized prostate cancer.
|
Arch Intern Med
|
2010
|
4.11
|
|
3
|
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
|
JAMA
|
2004
|
4.10
|
|
4
|
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions.
|
Int J Radiat Oncol Biol Phys
|
2008
|
3.78
|
|
5
|
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience.
|
Int J Radiat Oncol Biol Phys
|
2005
|
2.75
|
|
6
|
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
|
J Urol
|
2007
|
2.69
|
|
7
|
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
|
Int J Radiat Oncol Biol Phys
|
2003
|
2.58
|
|
8
|
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
|
Eur Urol
|
2012
|
2.45
|
|
9
|
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
|
Cancer
|
2010
|
2.42
|
|
10
|
Fluoroscopically guided interventional procedures: a review of radiation effects on patients' skin and hair.
|
Radiology
|
2010
|
2.36
|
|
11
|
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
|
Eur Urol
|
2013
|
2.33
|
|
12
|
Androgen receptor signaling regulates DNA repair in prostate cancers.
|
Cancer Discov
|
2013
|
2.15
|
|
13
|
High-risk prostate cancer: from definition to contemporary management.
|
Eur Urol
|
2012
|
2.06
|
|
14
|
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.
|
Brachytherapy
|
2012
|
2.03
|
|
15
|
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
|
J Clin Oncol
|
2006
|
1.97
|
|
16
|
Salvage re-irradiation for recurrent head and neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.91
|
|
17
|
Intensity-modulated radiation therapy: supportive data for prostate cancer.
|
Semin Radiat Oncol
|
2008
|
1.91
|
|
18
|
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.83
|
|
19
|
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
|
Eur Urol
|
2011
|
1.81
|
|
20
|
Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.80
|
|
21
|
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.77
|
|
22
|
Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.69
|
|
23
|
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging.
|
Radiology
|
2006
|
1.69
|
|
24
|
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.68
|
|
25
|
Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.67
|
|
26
|
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.62
|
|
27
|
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.
|
Eur Urol
|
2013
|
1.60
|
|
28
|
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.58
|
|
29
|
Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity.
|
J Clin Oncol
|
2002
|
1.58
|
|
30
|
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.54
|
|
31
|
Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
|
J Clin Oncol
|
2003
|
1.51
|
|
32
|
Single-fraction intraoperative radiotherapy for breast cancer: early cosmetic results.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.50
|
|
33
|
Locally advanced prostate cancer: a population-based study of treatment patterns.
|
BJU Int
|
2011
|
1.46
|
|
34
|
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.
|
Cancer J
|
2006
|
1.42
|
|
35
|
Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantation.
|
Brachytherapy
|
2009
|
1.42
|
|
36
|
A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.39
|
|
37
|
Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients.
|
Brachytherapy
|
2013
|
1.38
|
|
38
|
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
|
Urology
|
2008
|
1.32
|
|
39
|
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.32
|
|
40
|
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.31
|
|
41
|
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.29
|
|
42
|
American Cancer Society prostate cancer survivorship care guidelines.
|
CA Cancer J Clin
|
2014
|
1.29
|
|
43
|
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.28
|
|
44
|
Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.
|
J Clin Oncol
|
2003
|
1.27
|
|
45
|
Comparison of biochemical failure definitions for permanent prostate brachytherapy.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.27
|
|
46
|
Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.25
|
|
47
|
Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
|
J Urol
|
2005
|
1.23
|
|
48
|
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.21
|
|
49
|
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.17
|
|
50
|
Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.15
|
|
51
|
Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results.
|
Eur Radiol
|
2011
|
1.13
|
|
52
|
Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.13
|
|
53
|
Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.12
|
|
54
|
Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.11
|
|
55
|
Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
|
BJU Int
|
2014
|
1.10
|
|
56
|
Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT.
|
Brachytherapy
|
2010
|
1.09
|
|
57
|
Intensity-modulated radiotherapy.
|
Cancer J
|
2002
|
1.07
|
|
58
|
Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.06
|
|
59
|
A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development.
|
Clin Prostate Cancer
|
2005
|
1.04
|
|
60
|
Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer.
|
Brachytherapy
|
2006
|
1.04
|
|
61
|
Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
1.02
|
|
62
|
Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer.
|
Semin Oncol
|
2003
|
1.00
|
|
63
|
Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer.
|
Radiother Oncol
|
2002
|
1.00
|
|
64
|
New treatments for localized prostate cancer.
|
Urology
|
2008
|
0.98
|
|
65
|
Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?
|
Radiology
|
2013
|
0.97
|
|
66
|
Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer.
|
Int J Cancer
|
2013
|
0.96
|
|
67
|
Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
|
Brachytherapy
|
2005
|
0.96
|
|
68
|
Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques.
|
Am J Clin Oncol
|
2003
|
0.96
|
|
69
|
Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity.
|
Ann Surg Oncol
|
2002
|
0.96
|
|
70
|
Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis.
|
Cancer
|
2006
|
0.95
|
|
71
|
Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy.
|
Radiother Oncol
|
2009
|
0.95
|
|
72
|
Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.94
|
|
73
|
Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?
|
Lancet Oncol
|
2012
|
0.93
|
|
74
|
Conventional treatments of localized prostate cancer.
|
Urology
|
2008
|
0.92
|
|
75
|
Radiotherapy after surgical resection for head and neck mucosal melanoma.
|
Am J Clin Oncol
|
2010
|
0.92
|
|
76
|
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.90
|
|
77
|
Tolerance of tissue transfers to adjuvant radiation therapy in primary soft tissue sarcoma of the extremity.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.90
|
|
78
|
Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx.
|
Ann Surg
|
2003
|
0.90
|
|
79
|
Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.90
|
|
80
|
Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.
|
Cancer
|
2009
|
0.89
|
|
81
|
Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.89
|
|
82
|
Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcomes, and toxicity.
|
Head Neck
|
2008
|
0.88
|
|
83
|
Assessment of radiation safety instructions to patients based on measured dose rates following prostate brachytherapy.
|
Brachytherapy
|
2004
|
0.88
|
|
84
|
Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
|
Brachytherapy
|
2012
|
0.88
|
|
85
|
A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.
|
Brachytherapy
|
2013
|
0.87
|
|
86
|
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.87
|
|
87
|
Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI.
|
Eur Radiol
|
2015
|
0.87
|
|
88
|
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
|
Urology
|
2006
|
0.86
|
|
89
|
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.
|
Clin Cancer Res
|
2009
|
0.86
|
|
90
|
High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
|
Brachytherapy
|
2007
|
0.84
|
|
91
|
The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
|
Cancer
|
2003
|
0.83
|
|
92
|
Development of a semi-automatic alignment tool for accelerated localization of the prostate.
|
Int J Radiat Oncol Biol Phys
|
2003
|
0.82
|
|
93
|
Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer.
|
Am J Clin Oncol
|
2008
|
0.81
|
|
94
|
A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer.
|
Brachytherapy
|
2011
|
0.81
|
|
95
|
Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer.
|
Med Phys
|
2008
|
0.81
|
|
96
|
Using QRRO survey data to assess compliance with quality indicators for breast and prostate cancer.
|
J Am Coll Radiol
|
2009
|
0.81
|
|
97
|
How to select the optimal therapy for early-stage prostate cancer.
|
Crit Rev Oncol Hematol
|
2012
|
0.81
|
|
98
|
Endoluminal high-dose-rate brachytherapy for early stage and recurrent esophageal cancer in medically inoperable patients.
|
Brachytherapy
|
2013
|
0.80
|
|
99
|
What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
|
Nat Clin Pract Urol
|
2008
|
0.80
|
|
100
|
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
|
Brachytherapy
|
2005
|
0.79
|
|
101
|
Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.79
|
|
102
|
Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.79
|
|
103
|
Intraoperative high-dose-rate brachytherapy using dose painting technique: evaluation of safety and preliminary clinical outcomes.
|
Brachytherapy
|
2012
|
0.79
|
|
104
|
High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.79
|
|
105
|
Location and number of positive surgical margins as prognostic factors of biochemical recurrence after salvage radiation therapy after radical prostatectomy.
|
BJU Int
|
2010
|
0.78
|
|
106
|
Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.78
|
|
107
|
The Anderson nomograms for permanent interstitial prostate implants: a briefing for practitioners.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.78
|
|
108
|
Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.77
|
|
109
|
How to select the optimal therapy for early-stage prostate cancer.
|
Crit Rev Oncol Hematol
|
2011
|
0.77
|
|
110
|
Comparing contemporary surgery to external-beam radiotherapy for clinically localized prostate cancer.
|
J Clin Oncol
|
2002
|
0.77
|
|
111
|
High-dose-rate intraoperative brachytherapy and radical surgical resection in the management of recurrent head-and-neck cancer.
|
Brachytherapy
|
2013
|
0.77
|
|
112
|
Long-Term Survival After High-Dose-Rate Brachytherapy for Locally Advanced or Recurrent Colorectal Adenocarcinoma.
|
Ann Surg Oncol
|
2015
|
0.77
|
|
113
|
Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.
|
Prostate
|
2014
|
0.77
|
|
114
|
A study of the effects of internal organ motion on dose escalation in conformal prostate treatments.
|
Radiother Oncol
|
2003
|
0.76
|
|
115
|
The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.
|
Cancer
|
2002
|
0.76
|
|
116
|
Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
|
Urology
|
2004
|
0.76
|
|
117
|
MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer.
|
Eur J Radiol
|
2013
|
0.76
|
|
118
|
Brachytherapy for clinically localized prostate cancer: optimal patient selection.
|
Arch Esp Urol
|
2011
|
0.76
|
|
119
|
Brachytherapy and MRI: seeing what we are missing.
|
Brachytherapy
|
2013
|
0.75
|
|
120
|
Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
|
Eur Urol
|
2013
|
0.75
|
|
121
|
Rebuttal to Dr. Stone.
|
Brachytherapy
|
2013
|
0.75
|
|
122
|
Prostate cancer: challenges in selecting the optimal therapy.
|
Nat Rev Urol
|
2012
|
0.75
|
|
123
|
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
|
Prostate
|
2014
|
0.75
|
|
124
|
Improved survival with surgery in prostate cancer patients without medical comorbidity: a self-fulfilling prophecy?
|
Eur Urol
|
2013
|
0.75
|
|
125
|
Which patients with prostate cancer benefit from immediate postoperative radiotherapy?
|
Nat Clin Pract Oncol
|
2008
|
0.75
|
|
126
|
The role of external beam in brachytherapy.
|
Future Oncol
|
2007
|
0.75
|
|
127
|
Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience.
|
Brachytherapy
|
2003
|
0.75
|
|
128
|
The current state of brachytherapy nomograms for patients with clinically localized prostate cancer.
|
Cancer
|
2009
|
0.75
|
|
129
|
Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
|
BJU Int
|
2013
|
0.75
|
|
130
|
TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome.
|
Laryngoscope
|
2012
|
0.75
|
|
131
|
Perspectives for 2012 from the editor-in-chief.
|
Brachytherapy
|
2012
|
0.75
|
|
132
|
Time trends in organ position and volume in patients receiving prostate three-dimensional conformal radiotherapy.
|
Radiother Oncol
|
2002
|
0.75
|